Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a placebo-controlled, German, Phase II trial in 745 volunteers, Imvamune met
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury